GAINESVILLE, Fla.--(BUSINESS WIRE)--
Exactech, Inc. (EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the international launch of Optetrak Logic® Porous, a new porous technology for total knee arthroplasty.
Logic Porous offers knee surgeons a new implant coating that strikes the balance between material strength, pore size and porosity. Its unique structural lattice developed through layers of irregular shaped beads results in an increased average pore size and greater porosity than traditional spherical beads.1
A University of New South Wales animal study compared the Logic Porous to traditional porous-beaded coating.1 The animal study, which used an established ovine model, demonstrated: greater shear strength at the cortical interface after 12 weeks of implantation; higher overall bone in-growth rates at the cancellous interface after 12 weeks of implantation; higher total bone in-growth rates at the cortical interface after four and 12 weeks of implantation; and greater forgiveness to sub-optimal implantation conditions. The study will be first presented at the European Orthopaedic Research Society 22nd Annual Meeting July 2-4.
“The addition of Optetrak Logic Porous strengthens Exactech’s knee product offerings, demonstrating our continued commitment to providing our surgeon customers with a comprehensive knee system that fits their clinical needs,” Exactech CEO David Petty said.
The launch coincides with the 20th anniversary of the Exactech Knee, a clinically-recognized system of proven implants and personalized surgical techniques, which includes the Optetrak® lineage of implants and ExactechGPS® Guided Personalized Surgery. This is the initial launch of Logic Porous internationally, with full market availability ramping up throughout 2014 and beyond.
Logic Porous is indicated for cemented use only in the U.S.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
1. Data on file at Exactech, Inc.
Jody Phillips, 352-377-1140
Chief Financial Officer
Julie Marshall or Frank Hawkins, 305-451-1888
Priscilla Bennett, 352-377-1140
Director Marketing Communication & Public Relations